FY2025 EPS Estimates for ASND Lifted by Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND) – Stock analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for Ascendis Pharma A/S in a research report issued to clients and investors on Monday, October 13th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biotechnology company will post earnings per share of ($1.81) for the year, up from their previous estimate of ($2.04). Cantor Fitzgerald currently has a “Overweight” rating and a $254.00 price target on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($4.34) per share. Cantor Fitzgerald also issued estimates for Ascendis Pharma A/S’s FY2026 earnings at $3.68 EPS.

Other analysts have also recently issued research reports about the company. Morgan Stanley began coverage on Ascendis Pharma A/S in a research report on Thursday, July 3rd. They set an “overweight” rating and a $250.00 target price for the company. Wall Street Zen cut Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Friday, September 5th. Wells Fargo & Company restated an “overweight” rating and set a $295.00 price target (up previously from $289.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Citigroup restated a “buy” rating and set a $290.00 price target (up previously from $243.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Finally, JPMorgan Chase & Co. raised their price target on Ascendis Pharma A/S from $260.00 to $264.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Fifteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $248.29.

Ascendis Pharma A/S Trading Down 0.8%

NASDAQ:ASND opened at $207.12 on Wednesday. Ascendis Pharma A/S has a 12-month low of $118.03 and a 12-month high of $216.45. The stock has a 50-day moving average price of $198.44 and a 200 day moving average price of $176.71. The stock has a market capitalization of $12.78 billion, a P/E ratio of -40.14 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.49. The business had revenue of $216.28 million for the quarter, compared to analysts’ expectations of $163.17 million.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC raised its holdings in Ascendis Pharma A/S by 115.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 256 shares during the period. Toth Financial Advisory Corp raised its holdings in Ascendis Pharma A/S by 33.7% during the 3rd quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 150 shares during the period. Whalen Wealth Management Inc. purchased a new stake in Ascendis Pharma A/S during the 3rd quarter valued at $919,000. GAMMA Investing LLC raised its holdings in Ascendis Pharma A/S by 15.2% during the 3rd quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 97 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Ascendis Pharma A/S by 0.6% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,186 shares of the biotechnology company’s stock valued at $2,103,000 after buying an additional 73 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.